The primary clinical goals of this multi-center clinical trial on HIV+ kidney transplant recipients are to evaluate the impact of CCR5 blockade (maraviroc, MVC) on renal function at week 52 post-transplant; as well as evaluate the overall safety and tolerability of CCR5 blockade in the HIV+ kidney transplant recipient.
Main Areas of Focus
The primary mechanistic goals of this trial are:
- To define immunologic parameters associated with rejection in the HIV positive recipient (versus HIV+ non-rejectors)
- To determine the impact of CCR5 blockade on the immunologic profiles in the HIV positive recipient
Content last reviewed on